XL765 (SAR245409)
Sponsors
Sanofi
Conditions
Astrocytoma, Grade IVBreast CancerCancerGlioblastomaGlioblastoma MultiformeMalignant GliomasMixed GliomasNon-Small Cell Lung Cancer
Phase 1
Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors
CompletedNCT00485719
Start: 2007-06-30End: 2012-09-30Updated: 2013-05-30
A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas
CompletedNCT00704080
Start: 2008-08-31End: 2013-02-28Updated: 2013-04-10
Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors
CompletedNCT00777699
Start: 2008-08-31End: 2011-02-28Updated: 2012-02-03
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer
CompletedNCT01082068
Start: 2010-06-30End: 2013-04-30Updated: 2016-06-03
Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
CompletedNCT01240460
Start: 2011-01-31End: 2012-06-30Updated: 2012-07-27